Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.4000
- TODAY'S CHANGE (%)-0.2500 (-4.4248%)
- Bid / Lots5.1000/ 1
- Ask / Lots5.8000/ 1
- Open / Previous Close5.6700 / 5.6500
- Day Range
- 52 Week Range
- Volume486,603
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 6356 | 5.65 |
| 09:34 ET | 1365 | 5.59 |
| 09:38 ET | 703 | 5.66 |
| 09:39 ET | 500 | 5.65 |
| 09:41 ET | 896 | 5.69 |
| 09:43 ET | 1152 | 5.648814 |
| 09:45 ET | 1300 | 5.635 |
| 09:48 ET | 1942 | 5.6135 |
| 09:50 ET | 3748 | 5.565 |
| 09:52 ET | 5363 | 5.525 |
| 09:54 ET | 2878 | 5.555 |
| 09:56 ET | 3188 | 5.51 |
| 09:57 ET | 1093 | 5.505 |
| 09:59 ET | 7078 | 5.51 |
| 10:01 ET | 934 | 5.51 |
| 10:03 ET | 6079 | 5.52 |
| 10:06 ET | 1808 | 5.51 |
| 10:08 ET | 1953 | 5.53 |
| 10:10 ET | 17707 | 5.545 |
| 10:12 ET | 1721 | 5.56 |
| 10:14 ET | 1786 | 5.55 |
| 10:15 ET | 855 | 5.53 |
| 10:17 ET | 1826 | 5.55 |
| 10:19 ET | 2800 | 5.54 |
| 10:21 ET | 626 | 5.52 |
| 10:24 ET | 2575 | 5.54 |
| 10:26 ET | 600 | 5.53 |
| 10:28 ET | 1257 | 5.55 |
| 10:30 ET | 1781 | 5.52 |
| 10:32 ET | 354 | 5.53 |
| 10:33 ET | 564 | 5.52 |
| 10:35 ET | 1148 | 5.55 |
| 10:37 ET | 655 | 5.56 |
| 10:39 ET | 3826 | 5.55 |
| 10:42 ET | 1758 | 5.555 |
| 10:44 ET | 1299 | 5.55 |
| 10:48 ET | 1700 | 5.58 |
| 10:50 ET | 200 | 5.57 |
| 10:51 ET | 400 | 5.57 |
| 10:53 ET | 1500 | 5.57 |
| 10:55 ET | 856 | 5.56 |
| 10:57 ET | 800 | 5.56 |
| 11:00 ET | 400 | 5.55 |
| 11:02 ET | 3150 | 5.5455 |
| 11:04 ET | 700 | 5.56 |
| 11:06 ET | 612 | 5.55 |
| 11:08 ET | 589 | 5.57 |
| 11:09 ET | 500 | 5.56 |
| 11:11 ET | 700 | 5.57 |
| 11:13 ET | 1024 | 5.5585 |
| 11:15 ET | 516 | 5.55 |
| 11:18 ET | 100 | 5.555 |
| 11:20 ET | 600 | 5.56 |
| 11:22 ET | 300 | 5.55 |
| 11:24 ET | 100 | 5.55 |
| 11:26 ET | 100 | 5.54 |
| 11:27 ET | 1475 | 5.53 |
| 11:29 ET | 300 | 5.54 |
| 11:31 ET | 13839 | 5.5 |
| 11:36 ET | 355 | 5.51 |
| 11:44 ET | 100 | 5.51 |
| 11:45 ET | 803 | 5.51 |
| 11:47 ET | 800 | 5.525 |
| 11:49 ET | 200 | 5.52 |
| 11:54 ET | 200 | 5.53 |
| 11:56 ET | 100 | 5.525 |
| 11:58 ET | 1347 | 5.51 |
| 12:00 ET | 100 | 5.51 |
| 12:02 ET | 590 | 5.51 |
| 12:03 ET | 270 | 5.51 |
| 12:05 ET | 200 | 5.51 |
| 12:07 ET | 1963 | 5.48 |
| 12:14 ET | 201 | 5.49 |
| 12:16 ET | 9084 | 5.48 |
| 12:18 ET | 227 | 5.49 |
| 12:20 ET | 1837 | 5.53 |
| 12:23 ET | 164 | 5.525 |
| 12:25 ET | 20370 | 5.43 |
| 12:27 ET | 5866 | 5.48 |
| 12:30 ET | 500 | 5.47 |
| 12:34 ET | 500 | 5.47 |
| 12:38 ET | 1459 | 5.48 |
| 12:39 ET | 800 | 5.51 |
| 12:41 ET | 3312 | 5.51 |
| 12:43 ET | 300 | 5.515 |
| 12:45 ET | 825 | 5.51 |
| 12:48 ET | 100 | 5.51 |
| 12:50 ET | 220 | 5.51 |
| 12:52 ET | 200 | 5.52 |
| 12:54 ET | 1204 | 5.51 |
| 12:57 ET | 100 | 5.51 |
| 12:59 ET | 200 | 5.515 |
| 01:01 ET | 600 | 5.5 |
| 01:06 ET | 1100 | 5.52 |
| 01:08 ET | 100 | 5.52 |
| 01:10 ET | 100 | 5.52 |
| 01:12 ET | 1000 | 5.51 |
| 01:14 ET | 400 | 5.49 |
| 01:19 ET | 2130 | 5.51 |
| 01:21 ET | 1037 | 5.5 |
| 01:24 ET | 100 | 5.5 |
| 01:26 ET | 2000 | 5.5 |
| 01:28 ET | 513 | 5.49 |
| 01:30 ET | 300 | 5.49 |
| 01:32 ET | 1387 | 5.49 |
| 01:33 ET | 3986 | 5.43 |
| 01:35 ET | 2988 | 5.44 |
| 01:37 ET | 1473 | 5.45 |
| 01:39 ET | 1612 | 5.48 |
| 01:42 ET | 1237 | 5.48 |
| 01:44 ET | 100 | 5.46 |
| 01:51 ET | 524 | 5.48 |
| 01:53 ET | 795 | 5.4716 |
| 01:55 ET | 200 | 5.49 |
| 01:57 ET | 200 | 5.5 |
| 02:00 ET | 1400 | 5.5 |
| 02:02 ET | 500 | 5.5 |
| 02:04 ET | 1618 | 5.48 |
| 02:06 ET | 100 | 5.49 |
| 02:08 ET | 300 | 5.49 |
| 02:09 ET | 300 | 5.49 |
| 02:11 ET | 100 | 5.485 |
| 02:13 ET | 300 | 5.4809 |
| 02:15 ET | 6593 | 5.49 |
| 02:18 ET | 100 | 5.48 |
| 02:20 ET | 480 | 5.48 |
| 02:22 ET | 1600 | 5.44 |
| 02:26 ET | 3220 | 5.45 |
| 02:27 ET | 1459 | 5.46 |
| 02:29 ET | 100 | 5.47 |
| 02:31 ET | 214 | 5.4605 |
| 02:33 ET | 5338 | 5.45 |
| 02:36 ET | 413 | 5.459 |
| 02:40 ET | 100 | 5.45 |
| 02:42 ET | 200 | 5.45 |
| 02:44 ET | 100 | 5.45 |
| 02:45 ET | 2325 | 5.43 |
| 02:47 ET | 100 | 5.43 |
| 02:49 ET | 100 | 5.42 |
| 02:51 ET | 1493 | 5.415 |
| 02:54 ET | 869 | 5.4 |
| 02:56 ET | 449 | 5.402 |
| 02:58 ET | 300 | 5.41 |
| 03:00 ET | 2540 | 5.43 |
| 03:02 ET | 400 | 5.43 |
| 03:03 ET | 100 | 5.44 |
| 03:07 ET | 100 | 5.44 |
| 03:09 ET | 300 | 5.44 |
| 03:12 ET | 2038 | 5.45 |
| 03:16 ET | 1479 | 5.49 |
| 03:18 ET | 162 | 5.5 |
| 03:20 ET | 100 | 5.49 |
| 03:21 ET | 2500 | 5.47 |
| 03:23 ET | 170 | 5.48 |
| 03:25 ET | 300 | 5.48 |
| 03:30 ET | 9616 | 5.46 |
| 03:32 ET | 500 | 5.46 |
| 03:34 ET | 784 | 5.4597 |
| 03:36 ET | 600 | 5.45 |
| 03:38 ET | 1225 | 5.45 |
| 03:41 ET | 371 | 5.4578 |
| 03:43 ET | 200 | 5.45 |
| 03:45 ET | 735 | 5.45 |
| 03:48 ET | 400 | 5.45 |
| 03:50 ET | 10149 | 5.48 |
| 03:52 ET | 500 | 5.48 |
| 03:54 ET | 5278 | 5.455 |
| 03:56 ET | 1376 | 5.455 |
| 03:57 ET | 3326 | 5.45 |
| 03:59 ET | 95323 | 5.4 |
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 335.7M | -8.5x | --- |
Nkarta Inc | 335.2M | -2.3x | --- |
Jasper Therapeutics Inc | 329.1M | -3.6x | --- |
Inozyme Pharma Inc | 328.1M | -3.5x | --- |
Korro Bio Inc | 325.7M | -1.1x | --- |
Corvus Pharmaceuticals Inc | 324.0M | -11.7x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $335.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
